Delegated price-control norms remain valid when based on relevant material, and retail pricing need not await bulk drug fixation.

The article examines delegated price-control under the Drugs (Prices Control) Order, 1995 and explains that expert-based norms for conversion cost, packing charges and process loss were treated as valid when supported by available material and not shown to be arbitrary. It also discusses that yearly re-determination of those norms was not regarded as mandatory where the underlying data remained unchanged and industry non-cooperation prevented a fresh study. The text further notes that retail or ceiling price fixation could proceed without a separately prescribed packing material norm and without first fixing a bulk drug price, because the scheme did not make bulk-drug pricing a pre-condition for formulation pricing. Judicial review is described as limited to application of the statutory formula on relevant material.

---

---

Issues: (i) Whether the notification dated 13 July 1999 prescribing norms for conversion cost, packing charges and process loss under Paragraph 7 of the Drugs (Prices Control) Order, 1995 was issued mechanically and without application of mind; (ii) Whether the notifications dated 12 July 2000, 12 July 2001, 12 July 2002 and 11 July 2003 re-notifying those norms were invalid for want of yearly re-determination; (iii) Whether price notifications issued under Paragraphs 8 and 9 of the Drugs (Prices Control) Order, 1995 were invalid for not separately prescribing a norm for packing material cost; (iv) Whether fixation of retail price under Paragraph 8 could be done without first fixing the bulk drug price under Paragraph 3.

Issue (i): Whether the notification dated 13 July 1999 prescribing norms for conversion cost, packing charges and process loss under Paragraph 7 of the Drugs (Prices Control) Order, 1995 was issued mechanically and without application of mind.

Analysis: The notification followed consideration of successive expert reports and the available material, including the reports of the Sankaran Committee, the Masood Committee and the Jharwal Committee. The drug industry did not cooperate fully with the data-gathering exercise, and the Central Government was required to act on the material that was available. In that situation, the decision-making process could not be treated as arbitrary or devoid of consideration.

Conclusion: The notification dated 13 July 1999 was valid and was not issued mechanically or without application of mind.

Issue (ii): Whether the notifications dated 12 July 2000, 12 July 2001, 12 July 2002 and 11 July 2003 re-notifying those norms were invalid for want of yearly re-determination.

Analysis: Paragraph 7 required the formula to be applied for price fixation, but yearly re-determination of norms was not treated as an inflexible ritual where the circumstances did not justify change. The existing norms could be continued by re-notification where the materials remained unchanged and the industry's non-cooperation prevented a fresh study. Paragraphs 8(5) and 27 of the Drugs (Prices Control) Order, 1995 also supported continuity during the transition.

Conclusion: The re-notifications were valid and yearly re-determination was not mandatory in the circumstances.

Issue (iii): Whether price notifications issued under Paragraphs 8 and 9 of the Drugs (Prices Control) Order, 1995 were invalid for not separately prescribing a norm for packing material cost.

Analysis: The record showed that packing material cost had long been taken on actuals and that the industry had not objected to that arrangement. Expert bodies found that prescribing a separate packing material norm in isolation was not necessary and would not materially assist the pricing exercise. The absence of such a norm did not render the price notifications unsustainable.

Conclusion: The notifications fixing retail price or ceiling price remained valid despite the absence of a separate packing material norm.

Issue (iv): Whether fixation of retail price under Paragraph 8 could be done without first fixing the bulk drug price under Paragraph 3.

Analysis: The scheme of the Drugs (Prices Control) Order, 1995 did not make fixation of a bulk drug price a pre-condition for fixing the retail price of a formulation. A formulation may contain one or more bulk drugs, and the inability or absence of bulk-drug price fixation could not disable retail price fixation under the Order.

Conclusion: Retail price fixation under Paragraph 8 was valid even without first fixing the bulk drug price under Paragraph 3.

Final Conclusion: The Central Government's notifications were upheld, the challenges to the price-control measures failed, and the batch of appeals was disposed of by allowing the Union of India's appeals and dismissing the challenge by Dr. Reddy's Laboratories Ltd.

Ratio Decidendi: In delegated price-control legislation, judicial review is limited to whether the statutory formula was applied on relevant material and without arbitrariness; expert-based norms and their re-notification need not be struck down merely because the affected industry did not cooperate or because the court might have preferred a different economic assessment.

---